U.S. markets open in 3 hours 15 minutes
  • S&P Futures

    3,885.75
    -13.00 (-0.33%)
     
  • Dow Futures

    31,443.00
    -66.00 (-0.21%)
     
  • Nasdaq Futures

    13,233.75
    -46.00 (-0.35%)
     
  • Russell 2000 Futures

    2,257.40
    -17.40 (-0.76%)
     
  • Crude Oil

    60.67
    +0.03 (+0.05%)
     
  • Gold

    1,725.00
    +2.00 (+0.12%)
     
  • Silver

    26.34
    -0.33 (-1.25%)
     
  • EUR/USD

    1.2031
    -0.0029 (-0.24%)
     
  • 10-Yr Bond

    1.4460
    0.0000 (0.00%)
     
  • Vix

    23.47
    -4.48 (-16.03%)
     
  • GBP/USD

    1.3905
    -0.0016 (-0.12%)
     
  • USD/JPY

    106.9100
    +0.1800 (+0.17%)
     
  • BTC-USD

    48,830.82
    +1,632.94 (+3.46%)
     
  • CMC Crypto 200

    981.94
    -4.71 (-0.48%)
     
  • FTSE 100

    6,626.82
    +38.29 (+0.58%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 14, 2020 at 5:00 p.m. ET to report first quarter 2020 financial results and discuss recent business highlights.

To access the live conference call, please dial 1-866-930-5579 (domestic) or 1-409-216-0606 (international) and refer to conference ID 2094044. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Investor & Media Contact:
Nick Smith
Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com
847-871-0377

Source: Aptinyx Inc.